Free Trial
NASDAQ:GLTO

Galecto Q4 2023 Earnings Report

Galecto logo
$2.98 -0.03 (-0.83%)
Closing price 09/5/2025 03:58 PM Eastern
Extended Trading
$2.98 +0.00 (+0.17%)
As of 09/5/2025 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto EPS Results

Actual EPS
-$5.75
Consensus EPS
-$7.75
Beat/Miss
Beat by +$2.00
One Year Ago EPS
N/A

Galecto Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galecto Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 8, 2024
Conference Call Time
3:00AM ET

Upcoming Earnings

Galecto's Q3 2025 earnings is scheduled for Friday, November 7, 2025, with a conference call scheduled on Tuesday, November 4, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Galecto Earnings Headlines

Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
See More Galecto Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galecto? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galecto and other key companies, straight to your email.

About Galecto

Galecto (NASDAQ:GLTO), a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

View Galecto Profile

More Earnings Resources from MarketBeat